Short Interest in Celsion Co. (CLSN) Expands By 44.0%

Celsion Co. (NASDAQ:CLSN) was the target of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 1,719,534 shares, a growth of 44.0% from the November 15th total of 1,193,756 shares. Based on an average daily volume of 5,485,704 shares, the days-to-cover ratio is currently 0.3 days. Currently, 10.8% of the shares of the stock are short sold.

Celsion (NASDAQ CLSN) opened at $2.59 on Wednesday. Celsion has a one year low of $1.24 and a one year high of $8.82.

An institutional investor recently bought a new position in Celsion stock. Sabby Management LLC acquired a new stake in shares of Celsion Co. (NASDAQ:CLSN) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 108,843 shares of the biotechnology company’s stock, valued at approximately $223,000. Sabby Management LLC owned 1.30% of Celsion as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 3.97% of the company’s stock.

Several analysts have recently commented on the stock. Maxim Group upgraded shares of Celsion from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research report on Wednesday, October 4th. Zacks Investment Research lowered shares of Celsion from a “buy” rating to a “hold” rating in a research report on Tuesday, October 17th. ValuEngine upgraded shares of Celsion from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 9th. Finally, Oppenheimer assumed coverage on shares of Celsion in a research report on Tuesday, November 21st. They issued an “outperform” rating and a $9.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. Celsion presently has a consensus rating of “Buy” and a consensus target price of $11.90.

WARNING: “Short Interest in Celsion Co. (CLSN) Expands By 44.0%” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://sportsperspectives.com/2017/12/20/short-interest-in-celsion-co-clsn-expands-by-44-0.html.

Celsion Company Profile

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply